PetMed Express’ (PETS) “Underperform” Rating Reaffirmed at Credit Suisse Group
PetMed Express, Inc. (NASDAQ:PETS)‘s stock had its “underperform” rating restated by equities research analysts at Credit Suisse Group in a report released on Monday.
PETS has been the subject of a number of other research reports. ValuEngine upgraded PetMed Express from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. BidaskClub cut PetMed Express from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 22nd. Craig Hallum cut PetMed Express from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Sidoti upgraded PetMed Express from a “neutral” rating to a “buy” rating and set a $47.00 price objective on the stock in a research report on Thursday, August 24th. Finally, Zacks Investment Research lowered PetMed Express from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 25th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. PetMed Express presently has an average rating of “Hold” and an average target price of $44.75.
PetMed Express (NASDAQ PETS) traded up 1.51% during mid-day trading on Monday, hitting $33.65. 109,328 shares of the stock traded hands. The company has a market cap of $682.83 million, a price-to-earnings ratio of 25.88 and a beta of 1.03. PetMed Express has a 12-month low of $18.90 and a 12-month high of $50.90. The firm’s 50-day moving average is $40.97 and its 200-day moving average is $33.60.
PetMed Express (NASDAQ:PETS) last released its earnings results on Monday, July 24th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.07. PetMed Express had a return on equity of 28.67% and a net margin of 10.34%. The business had revenue of $79.66 million for the quarter, compared to the consensus estimate of $77.32 million. During the same period last year, the business earned $0.32 earnings per share. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. Equities research analysts expect that PetMed Express will post $1.44 EPS for the current year.
In other PetMed Express news, Director Robert C. Schweitzer sold 2,500 shares of PetMed Express stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $49.18, for a total transaction of $122,950.00. Following the sale, the director now directly owns 88,834 shares of the company’s stock, valued at $4,368,856.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Bruce S. Rosenbloom sold 6,833 shares of PetMed Express stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $50.18, for a total value of $342,879.94. Following the sale, the chief financial officer now directly owns 18,534 shares in the company, valued at $930,036.12. The disclosure for this sale can be found here. Insiders sold 19,333 shares of company stock valued at $949,730 in the last three months. Company insiders own 4.00% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of PETS. Pinebridge Investments L.P. lifted its position in shares of PetMed Express by 1.0% during the 2nd quarter. Pinebridge Investments L.P. now owns 2,704 shares of the company’s stock worth $110,000 after buying an additional 27 shares during the period. Acrospire Investment Management LLC bought a new stake in PetMed Express in the second quarter valued at $110,000. Fred Alger Management Inc. bought a new stake in PetMed Express in the second quarter valued at $162,000. State of Alaska Department of Revenue grew its position in PetMed Express by 76.7% in the second quarter. State of Alaska Department of Revenue now owns 4,028 shares of the company’s stock valued at $163,000 after acquiring an additional 1,748 shares during the period. Finally, Bayesian Capital Management LP bought a new stake in PetMed Express in the second quarter valued at $203,000. 78.91% of the stock is owned by institutional investors and hedge funds.
About PetMed Express
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.